Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. Recruitment is ongoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Alk-positive Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma
• T-cell Histiocyte-rich Large B-cell Lymphoma

Drugs mentioned

• Columvi (glofitamab)
• Polivy (polatuzumab vedotin)

Snippet

Sponsor: University of Washington | Conditions: Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 | Status: RECRUITING